Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2018

Global Markets Direct
112 Pages - GMD17615
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2018, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Cancer anorexia-cachexia syndrome or cancer cachexia is wasting of both adipose tissue and skeletal muscle in response to a malignant growth. Cachexia is present in the early stages of tumor growth before any signs or symptoms of malignancy. Symptoms include skeletal muscle wasting, weight loss and loss of appetite. Treatment includes appetite stimulants and change in life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
Table of Contents 2
Introduction 4
Cancer Anorexia-Cachexia Syndrome - Overview 5
Cancer Anorexia-Cachexia Syndrome - Therapeutics Development 6
Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment 13
Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development 21
Cancer Anorexia-Cachexia Syndrome - Drug Profiles 28
Cancer Anorexia-Cachexia Syndrome - Dormant Projects 94
Cancer Anorexia-Cachexia Syndrome - Discontinued Products 96
Cancer Anorexia-Cachexia Syndrome - Product Development Milestones 97
Appendix 108

List of Tables
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aphios Corp, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Energenesis Biomedical Co Ltd, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Fountain Biopharma Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Teijin Pharma Ltd, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Vascular BioSciences, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by XBiotech Inc, H2 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2018
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2018
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2018 (Contd..1), H2 2018
Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838